We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 60

Biosimilar battlegrounds - what is new in biosimilars and where?
  • Bereskin & Parr LLP
  • Canada, European Union, USA
  • February 17 2012

Biosimilars are second entry biologic drugs


Proactive pharma patent enforcement on Canadian drug combos
  • Bereskin & Parr LLP
  • Canada
  • May 14 2015

The Canadian Patented Medicine (Notice of Compliance) Regulations ("NOC Regulations") allow a patent owner to apply to Federal Court to keep a


Supreme Court dismisses appeal from the bench in Sanofi-Aventis v. Apotex, Inc.
  • Bereskin & Parr LLP
  • Canada
  • May 8 2015

On April 21st, 2015, the Supreme Court of Canada dismissed from the bench an appeal from the Federal Court of Appeal decision inApotex Inc. v


Canadian patent term extension is coming
  • Bereskin & Parr LLP
  • Canada, European Union
  • October 18 2013

Canada and Europe announced an agreement in principle on a Comprehensive Economic and Trade Agreement (“CETA”) that will potentially increase Canadian


Federal court overturns Commissioner of Patents: claims with fixed dosages and dosing schedules held not to be methods of medical treatment
  • Bereskin & Parr LLP
  • Canada
  • January 16 2015

In AbbVie Biotechnology Ltd v Canada (Attorney General) "AbbVie" the Federal Court allowed AbbVie's appeal of a decision by the Commissioner of


Monoclonal antibody claims get some support
  • Bereskin & Parr LLP
  • Canada
  • June 28 2011

In Re Immunex Corporation Patent Application No. 583,988, (2011) 89 C.P.R. (4th) 34, the Patent Appeal Board held that broad claims to monoclonal antibodies are allowable in the absence of a working example when the antigen is a novel polypeptide that has been fully characterized, for example, by its complete amino acid sequence


Sufficiently disclosing a promised utility
  • Bereskin & Parr LLP
  • Canada
  • June 28 2011

Pharmaceutical patent applicants are often confronted with the issue of whether to file a new drug patent application early or wait until more substantial data has been generated on a larger number of compounds


Federal Court invalidates Sanofi’s Plavix patent for alleged insufficiency and obviousness
  • Bereskin & Parr LLP
  • Canada
  • January 12 2012

On December 6, 2011, the Federal Court of Canada issued its decision in the well-known dispute between Apotex Inc. and Sanofi-Aventis over the anticoagulant drug, clopidogrel bisulfate, sold in Canada under the brand name Plavix


Europe discards embryonic stem cell patents
  • Bereskin & Parr LLP
  • Canada, European Union
  • December 15 2011

Adult stem cells, and processes for their manipulation, are generally patentable in Europe


An update on Canadian selection patents the Olanzapine saga
  • Bereskin & Parr LLP
  • Canada
  • December 15 2011

Eli Lilly’s Canadian patent no. 2,041,113 (‘113 patent), covering its successful drug Olanzapine, has been the subject of several court proceedings, including an infringement action which was appealed and subsequently remanded back to the trial division